What are the key takeaways from this The Biotech Startups Podcast episode?

Key insights include: **Proteomics market gap:** Current mass spectrometry workflows physically fragment proteins into peptides, then infer original sequences by weight — producing irreproducible data. Since 95% of FDA-approved drugs target proteins, this reproducibility failure directly limits drug discovery and AI-driven diagnostics. Researchers seeking reliable protein biomarkers should evaluate platforms that analyze intact molecules rather than inferred fragments.; **Iterative multi-probe identification:** Nautilus's platform spatially separates billions of molecules onto a chip at ~1-micron spacing, then repeatedly exposes each molecule to different antibodies, stacking hundreds of binding-event data points per molecule — similar to GPS triangulation across multiple signals. This eliminates the need for one dedicated antibody per protein variant, sidestepping a library of millions.; **Four-pillar hard-tech timeline:** Building Nautilus required four parallel development tracks — semiconductor flow-cell fabrication, a novel antibody probe library, a new iterative binding assay, and ML-based identification algorithms — each taking years independently. Founders tackling multi-pillar deep tech should budget roughly 10 years and $500M even with a clear technical roadmap, and expect each milestone to take longer than projected.

What did Sujal Patel discuss on The Biotech Startups Podcast?

Sujal Patel, co-founder and CEO of Nautilus Biotechnology, explains why proteomics remains scientifically underserved despite 95% of FDA-approved drugs targeting proteins, how Nautilus built four distinct technical pillars over nine years and ~$500M to analyze billions of protein molecules simultaneously, and what commercialization looks like starting in neurology. Key topics include: **Proteomics market gap:** Current mass spectrometry workflows physically fragment proteins into peptides, then infer original sequences by weight — producing irreproducible data. Since 95% of FDA-approved drugs target proteins, this reproducibility failure directly limits drug discovery and AI-driven diagnostics. Researchers seeking reliable protein biomarkers should evaluate platforms that analyze intact molecules rather than inferred fragments.; **Iterative multi-probe identification:** Nautilus's platform spatially separates billions of molecules onto a chip at ~1-micron spacing, then repeatedly exposes each molecule to different antibodies, stacking hundreds of binding-event data points per molecule — similar to GPS triangulation across multiple signals. This eliminates the need for one dedicated antibody per protein variant, sidestepping a library of millions..

How long is this episode of The Biotech Startups Podcast?

This episode is 39 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

The Biotech Startups Podcast

🧬 You Don’t See the Path, You Take the Next Step | Sujal Patel (Part 4/4)

March 12, 2026

39 min episode · 2 min read

Sujal Patel

Episode

39 min

Read time

2 min

Topics

Productivity, Relationships, Startups

AI-Generated Summary

Published Mar 16, 2026

Key Takeaways

✓Proteomics market gap: Current mass spectrometry workflows physically fragment proteins into peptides, then infer original sequences by weight — producing irreproducible data. Since 95% of FDA-approved drugs target proteins, this reproducibility failure directly limits drug discovery and AI-driven diagnostics. Researchers seeking reliable protein biomarkers should evaluate platforms that analyze intact molecules rather than inferred fragments.
✓Iterative multi-probe identification: Nautilus's platform spatially separates billions of molecules onto a chip at ~1-micron spacing, then repeatedly exposes each molecule to different antibodies, stacking hundreds of binding-event data points per molecule — similar to GPS triangulation across multiple signals. This eliminates the need for one dedicated antibody per protein variant, sidestepping a library of millions.
✓Four-pillar hard-tech timeline: Building Nautilus required four parallel development tracks — semiconductor flow-cell fabrication, a novel antibody probe library, a new iterative binding assay, and ML-based identification algorithms — each taking years independently. Founders tackling multi-pillar deep tech should budget roughly 10 years and $500M even with a clear technical roadmap, and expect each milestone to take longer than projected.
✓Managing PhD scientists in startups: PhD researchers default to risk-averse, completion-before-reporting work styles that conflict with startup iteration speed. Patel addressed this by separating the problem: learning the science himself via YouTube lectures at 2x speed and daily "dumb questions" sessions with co-founder Parag Malik, then developing separate management frameworks for scientific staff distinct from software engineering norms.
✓Commercialization entry strategy: Nautilus targets three buyer archetypes — existing mass spec users, genomics researchers expanding into proteomics, and biologists focused purely on answers. Initial instrument packages are priced at ~$1M, with annual consumable spend potentially reaching $1M per instrument at scale. Early access is concentrated in neurology, specifically tau proteoform research with partners including the Buck Institute and Allen Institute for Brain Sciences.

What It Covers

Sujal Patel, co-founder and CEO of Nautilus Biotechnology, explains why proteomics remains scientifically underserved despite 95% of FDA-approved drugs targeting proteins, how Nautilus built four distinct technical pillars over nine years and ~$500M to analyze billions of protein molecules simultaneously, and what commercialization looks like starting in neurology.

Key Questions Answered

•Proteomics market gap: Current mass spectrometry workflows physically fragment proteins into peptides, then infer original sequences by weight — producing irreproducible data. Since 95% of FDA-approved drugs target proteins, this reproducibility failure directly limits drug discovery and AI-driven diagnostics. Researchers seeking reliable protein biomarkers should evaluate platforms that analyze intact molecules rather than inferred fragments.
•Iterative multi-probe identification: Nautilus's platform spatially separates billions of molecules onto a chip at ~1-micron spacing, then repeatedly exposes each molecule to different antibodies, stacking hundreds of binding-event data points per molecule — similar to GPS triangulation across multiple signals. This eliminates the need for one dedicated antibody per protein variant, sidestepping a library of millions.
•Four-pillar hard-tech timeline: Building Nautilus required four parallel development tracks — semiconductor flow-cell fabrication, a novel antibody probe library, a new iterative binding assay, and ML-based identification algorithms — each taking years independently. Founders tackling multi-pillar deep tech should budget roughly 10 years and $500M even with a clear technical roadmap, and expect each milestone to take longer than projected.
•Managing PhD scientists in startups: PhD researchers default to risk-averse, completion-before-reporting work styles that conflict with startup iteration speed. Patel addressed this by separating the problem: learning the science himself via YouTube lectures at 2x speed and daily "dumb questions" sessions with co-founder Parag Malik, then developing separate management frameworks for scientific staff distinct from software engineering norms.
•Commercialization entry strategy: Nautilus targets three buyer archetypes — existing mass spec users, genomics researchers expanding into proteomics, and biologists focused purely on answers. Initial instrument packages are priced at ~$1M, with annual consumable spend potentially reaching $1M per instrument at scale. Early access is concentrated in neurology, specifically tau proteoform research with partners including the Buck Institute and Allen Institute for Brain Sciences.

Notable Moment

Patel states that even if he handed a large established company the complete technical blueprint for Nautilus's platform and personally led the replication effort, he would refuse the project — calling it too difficult for any major corporation to complete within a decade given the four simultaneous hard-tech pillars required.

Know someone who'd find this useful?

Episode Transcript

This episode is brought to you by Xcedar. Xcedar provides life science startups with equipment leases on founder friendly terms to accelerate r and d and commercialization. Lease the equipment you need with Xcedar. Extend your runway, hit your milestones, raise your next round at a favorable valuation, and achieve a blockbuster exit while minimizing dilution. Additionally, as a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code t b s p on exceda.com/partners. Welcome to the biotech startups podcast by Xida. Join us as we speak with first time founders, serial entrepreneurs, and experienced investors about the challenges and triumphs of running a biotech startup from pre seed to IPO with your host, John Chi. In our last episode, Soojil shared the intense EMC acquisition negotiation, calculating $33.85 per share on a Saturday phone call and serving as president of EMC's Isla storage division for two years. If you missed it, check out part three. In part four, Sujor unpacks taking four years between companies, evaluating biotech and clean energy ideas, and receiving an email from Parag Malik in 2016 that said, I think I've come up with something important. He also breaks down down why proteomics latter when 95% of FDA approved drugs target proteins, but current methods produce irreproducible data. How Nautilus's platform analyzes billions of molecules simultaneously using iterative antibody binding, and why building four technical pillars took half $1,000,000,000 and nine years. He reflects on learning to be a biotech CEO by watching YouTube chemistry lectures at two times speed, managing PhD scientists who think differently than tech engineers, and why the early access program with Tau Proteoforms presents a key commercialization milestone. What an origin story. And now you're like, okay. Frog's not crazy. Talk a little bit about the technology and, like, the state of the market and how this not crazy idea disrupts all of this. Yeah. Let's walk through, like, why is this an important challenge to go tackle. Right? So over the last decades, humanity has conquered genomics. If I take a drop your blood, I can tell you a few $100 what all your DNA is. All your gene your whole genome, I can tell you what's going on. The thing is that your genome doesn't really change from the day you're born to the day you die. And your genome is the same in every single one of the 37,000,000,000,000 cells for the most part that are in your body. So it gives you a very rough idea of what color your hair is gonna be. You might have propensity for this genetic disease, but it tells you nothing about the real time state in your body. All of your cells are made of proteins. Proteins do all of the work in your body. They're the little machines that do all the work. Because of that, 95% of our FDA approved …

Get the full transcript (7,372 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The Biotech Startups Podcast transcripts →